NXTC — NextCure, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1661059 ·
Last close
$6.70
Market Cap
$30.68M
52W High
$15.74
52W Low
$1.55
ADV30
63,864
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -8,963,000 | -6,846,000 | 9,700,000 | 8,728,000 | 4,197,000 |
| Jun 2026 | 0 | — | -10,017,000 | -14,892,000 | 22,620,000 | 15,260,000 | 10,471,000 |
| Mar 2026 | 0 | — | -10,105,000 | -9,796,000 | 37,977,000 | 15,167,000 | 11,261,000 |
| Dec 2025 | 0 | — | -9,757,000 | -9,436,000 | 50,183,000 | 25,982,000 | 15,240,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,790,000
Investing CF
$22,630,000
Financing CF
$21,564,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-9.18
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-467,514,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-38,842,000
Pretax Income TTM
$-40,970,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -57,616,000 | -55,844,000 | 50,183,000 | 15,240,000 | 34,943,000 | -49,613,000 |
| Dec 2024 | 0 | -57,206,000 | -55,654,000 | 80,860,000 | 15,388,000 | 65,472,000 | -40,805,000 |
| Dec 2023 | 0 | -67,637,000 | -62,723,000 | 128,038,000 | 13,617,000 | 114,421,000 | -52,974,000 |
| Dec 2022 | 0 | -75,909,000 | -74,733,000 | 184,161,000 | 16,631,000 | 167,530,000 | -53,886,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-42,748,000
OpCashFlow TTM
—
Assets (Latest)
$22,620,000
Forward EPS
$-5.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCTX | BriaCell Therapeutics Corp. | $30.65M | $3.51 | — |
| RNTX | Rein Therapeutics, Inc. | $30.75M | $0.36 | — |
| NSRX | Nasus Pharma Ltd | $30.57M | $2.61 | — |
| RLFTY | MindMaze Therapeutics Holding SA | $30.24M | $0.18 | — |
| TELO | Telomir Pharmaceuticals, Inc. | $31.17M | $0.42 | — |
News headlines (Yahoo Finance, 1h cache)
NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results
2026-11-10 21:05 · Yahoo
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
2026-08-06 20:01 · Yahoo
Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill
2026-07-14 12:00 · Yahoo
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
2026-05-04 11:05 · Yahoo
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
2026-04-21 14:15 · Yahoo
NextCure and Simcere’s SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
2026-03-31 20:05 · Yahoo
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
2026-04-07 12:05 · Yahoo
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
2026-05-07 20:05 · Yahoo
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
2026-06-01 12:00 · Yahoo
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
2026-06-04 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.